Prescription of antihypertensive medications during pregnancy in the UK

Authors

  • Lucia Cea Soriano,

    Corresponding author
    1. Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain
    2. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    • Correspondence to: L. Cea Soriano, Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain. E-mail: luciaceife@gmail.com

    Search for more papers by this author
  • Brian T. Bateman,

    1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
  • Luis A. García Rodríguez,

    1. Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain
    Search for more papers by this author
  • Sonia Hernández-Díaz

    1. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Search for more papers by this author

  • This manuscript has not been previously published and is not under consideration elsewhere. It has been presented in poster format at ICPE 2013.

ABSTRACT

Purpose

This study aimed to describe the management of antihypertensive medications in pregnancy by general practitioners in the UK and compare it with current guidelines.

Methods

We used electronic medical records from The Health Improvement Network database from 1996 to 2010 to identify completed pregnancies. The study cohort included the first pregnancy identified during the study period in women aged 13–49 years. Information on both hypertension diagnoses and prescription of specific antihypertensive medications within the 90 days before the last menstrual period (LMP) and during pregnancy was ascertained from electronic medical records.

Results

Among 148 544 eligible pregnancies, we identified 1995 (1.3%) during which the women had pre-existing hypertension diagnosed by the LMP date. Overall, the prevalence of antihypertensive medications during the first trimester was 1.5%; beta-blockers were the most commonly prescribed antihypertensive. Among women with pre-existing hypertension, 36% were prescribed an antihypertensive medication during the 90 days before the LMP. Among those, 9.6% and 22.2% had discontinued their medication by the first and second trimesters, respectively. For contraindicated drugs such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, the corresponding discontinuation rates were around 25% and 70%. Women who switched therapy received preferably either methyldopa or an alpha/beta-blocker.

Conclusions

In this population of UK pregnant women, prescription patterns of antihypertensive medications were dominated by recommended treatments, although some patients continued on contraindicated drugs throughout pregnancy or switched to preferred agents in a delayed fashion. Copyright © 2014 John Wiley & Sons, Ltd.

Ancillary